Tenofovir News and Research

RSS

Study provides new insights into real-world use of PrEP

Several studies presented today in an official press conference at the 21st International AIDS Conference in Durban provided new insights on the use of PrEP among a broad range of populations.

21 Jul 2016

Studies shed new light on why young women in South Africa experience high rates of HIV infection

Evidence by the Centre for the AIDS Programme of Research in South Africa (CAPRISA) consortium of South African and North American researchers will be presented on July 18 at the International AIDS 2016 Conference in Durban, shedding new light on why young women in South Africa have high rates of HIV infection.

18 Jul 2016

Researchers receive grant to test transcutaneously refillable implant that delivers HIV-prevention drugs

A Houston Methodist research team received a nearly $4 million grant to test a transcutaneously refillable implant that administers pre-exposure prophylaxis drugs to subjects at risk of HIV-exposure.

13 Jul 2016

TDF reduces vertical HBV transmission

The mother-to-child transmission of hepatitis B virus is reduced with tenofovir disoproxil fumarate treatment during the third trimester in pregnant chronic HBV patients with a high viral load, show the findings of a trial conducted in China.

4 Jul 2016

Maternal HBsAg can serve as HBV vertical transmission marker

Two studies have independently identified quantitative hepatitis B surface antigen as a marker to identify pregnant women with chronic hepatitis B virus infection whose infants are at high-risk of infection despite immunoprophylaxis.

23 Jun 2016

Topical delivery of AVR drug combination can provide complete protection against HIV

Researchers are edging ever closer to discovering the perfect combination of drugs and drug delivery system that will stop the sexual transmission of HIV.

14 Jun 2016

Nearly half of newly-infected HIV patients experience neurologic issues

A team led by researchers from UCSF and Yale has found that half of people newly infected with HIV experience neurologic issues. These neurologic findings are generally not severe and usually resolve after participants started anti-retroviral therapy.

14 Jun 2016

TDF, entecavir duo 'highly effective' for difficult-to-treat chronic HBV

The combination of tenofovir disoproxil fumarate and entecavir induces a high rate of viral suppression in patients with chronic hepatitis B virus infection who have failed multiple nucleos(t)ide analogue regimens, phase IIIb results indicate.

13 Apr 2016

Renal risk factors for NA-treated HBV patients identified

A South Korean research team has identified several clinical and medical factors associated with renal function decline in patients with chronic hepatitis B virus infection treated with oral nucleos(t)ide analogues.

10 Mar 2016

Real-world data confirm TDF efficacy for HBV

Treatment with tenofovir disoproxil fumarate elicits sustained virological responses and exhibits a favourable safety profile in a diverse population of patients with chronic hepatitis B virus infection, shows a French routine clinical practice study.

10 Mar 2016

Resistance to prior antiviral agents impacts TDF response

Taiwanese researchers find that virological response to tenofovir disoproxil fumarate in treatment-experienced patients with chronic hepatitis B virus infection can vary depending on the nucleos(t)ide analogue the patient is resistant to.

10 Mar 2016

Maraviroc drug safe, well-tolerated when taken as PrEP to prevent HIV infection

Maraviroc, an oral drug used to treat HIV infection, is safe and well-tolerated when taken daily as pre-exposure prophylaxis (PrEP) to prevent HIV infection by HIV-uninfected men who have sex with men (MSM) at increased risk for acquiring HIV.

25 Feb 2016

ARV drug atazanavir may have significant effects on infant development

The antiretroviral (ARV) drug atazanavir—sometimes included in treatments to prevent mother-to-child HIV transmission during pregnancy—may have small but significant effects on infant development, reports a study in the journal AIDS, official journal of the International AIDS Society.

23 Feb 2016

Rescue TDF monotherapy effective in multidrug resistant chronic HBV

Researchers from the Republic of Korea say that rescue therapy with tenofovir disoproxil fumarate alone is an appropriate option for patients with multidrug resistant chronic hepatitis B virus infection.

26 Jan 2016

Combining medications may increase HBsAg loss in HBV patients

Combining tenofovir disoproxil fumarate with pegylated interferon alfa-2a may improve the chances of hepatitis B surface antigen loss in patients with hepatitis B virus infection, suggests a randomised trial.

3 Dec 2015

Genvoya approved as complete regimen for HIV treatment

The U.S. Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.

6 Nov 2015

Vaginal silicone ring may protect women against HIV, herpes virus

Researchers at University Jean Monnet of Saint-Etienne, France have succeeded in developing a vaginal silicone ring that delivers molecules that act on both HIV and herpes virus. This research is presented at the 55th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC/ICC).

21 Sep 2015

Nurse-trainer uses new approach to teach correct combination of HIV drugs to Angola's nurses

Nurse-trainer Helena Cumbelembe Inacio was struggling to teach nurses at the health center here the correct combination of medicines to prevent pregnant women with HIV from passing the infection to their children.

11 Sep 2015

HIV prevention program undergoes “real world” evaluation

A programme that provides pre-exposure prophylaxis (PrEP) to prevent HIV infection among sexually active gay men has not seen one case of HIV infection since it began in 2012, according to the first “real world” evaluation of the regimen at Kaiser Permanente San Francisco Medical Center.

4 Sep 2015

IP10 levels linked to HBsAg decline during TDF treatment

Baseline serum interferon-inducible protein 10 levels predict hepatitis B surface antigen reduction in patients with hepatitis B e antigen-negative chronic hepatitis B virus infection treated with tenofovir disoproxil fumarate, findings indicate.

4 Aug 2015